The STOP Nitazenes Act amends the Controlled Substances Act by adding a new, class-based Schedule I entry for “2-benzylbenzimidazole opioids” (commonly called nitazenes). The amendment covers any material containing any quantity of those substances — including salts, isomers, and salts of isomers — and supplies a structural and pharmacological definition plus a list of named compounds; the Attorney General may publish an implementing list in the Federal Register.
The bill converts any nitazene that is currently temporarily scheduled under the CSA into a permanent Schedule I substance as of enactment and requires the Attorney General to issue implementing rules within one year, allowing an interim final rule that becomes immediately effective without the usual “good cause” showing. The change clears an enforcement path for federal prosecutors but also erects immediate regulatory and research barriers because Schedule I status triggers the CSA’s control and criminal provisions and DEA registration requirements.
At a Glance
What It Does
Adds a new subsection to 21 U.S.C. 812(c) that treats any material containing any quantity of a 2-benzylbenzimidazole opioid (and its salts/isomers) as a Schedule I controlled substance, defines that term by structural modifications and mu-opioid receptor activity, and lists several named nitazenes. It also deems temporarily scheduled nitazenes permanently scheduled and directs the Attorney General to issue implementing rules within one year, including an immediately effective interim final rule.
Who It Affects
Federal law enforcement and prosecutors, state/local forensic labs and medical examiners that test for nitazenes, DEA registrants and controlled-substance researchers, manufacturers and importers of chemical precursors, and harm-reduction programs that handle or test suspected nitazenes.
Why It Matters
This is a class-based scheduling approach rather than a case-by-case listing: it aims to prevent simple molecular tweaks from evading the law. That increases prosecutorial clarity but also broadens regulatory reach, with immediate compliance and research implications because Schedule I carries the strictest regulatory controls under the CSA.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a new, catch-all Schedule I entry into the Controlled Substances Act for a chemical family described as “2-benzylbenzimidazole opioids.” It does so by saying that, unless a substance is expressly exempted or placed in another schedule, any material that contains any quantity of such an opioid — including salts, isomers, and salts of isomers — falls squarely into Schedule I. The text mixes a chemical-structure definition (describing substitutions at several ring positions and common amine linkers), a pharmacological criterion (mu-opioid receptor agonist activity), and an enumerated list of familiar nitazene names.
Practically, that means trace contamination, derivative isomers, and designer analogues that fit the structural template will be treated under the CSA’s strict Schedule I regime unless an exemption applies. The bill also includes a clause letting the Attorney General publish a concrete list of covered substances in the Federal Register, which will be the practical reference point for labs and prosecutors.The bill makes an immediate conversion: anything temporarily scheduled under the CSA’s emergency scheduling authority for these substances becomes permanently Schedule I on enactment.
It then forces the Attorney General to adopt implementing rules within one year and allows those rules to go into effect immediately through an interim final rule without the usual “good cause” showing under the Administrative Procedure Act; the interim rule must still provide for comment and requests for hearings and ultimately be finalized under the APA.In effect, the statute operates on two tracks: (1) a broad, preventive scheduling tool aiming to capture current and potential future nitazene analogues; and (2) an administrative shortcut that lets the government lock in controls quickly while preserving a later opportunity for public comment. That combination creates immediate enforcement clarity but also immediate regulatory burdens on researchers, testing labs, and supply-chain actors who will need DEA registrations, security measures, recordkeeping, and possibly new testing protocols.
The Five Things You Need to Know
The bill adds a new subsection (f) to Schedule I of 21 U.S.C. 812(c) that makes “any material, compound, mixture, or preparation” containing any quantity of a 2-benzylbenzimidazole opioid a Schedule I controlled substance.
The statutory definition combines (A) structural chemistry descriptions (1- and 2-position substitutions and ring substitutions), (B) mu-opioid receptor agonist activity, and (C) a named list of compounds (including etonitazene, isotonitazene, protonitazene, butonitazene, and others).
The provision explicitly includes salts, isomers, and salts of isomers and permits the Attorney General to publish a Federal Register list of substances that satisfy the definition.
Any substance that was temporarily scheduled under 21 U.S.C. 811(h) and falls within this amendment is automatically deemed permanently Schedule I as of the date of enactment.
The Attorney General must issue implementing rules within one year and may use an interim final rule that becomes immediately effective without demonstrating good cause, but the rulemaking must allow comment and requests for hearings and later be finalized under APA section 553.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title — STOP Nitazenes Act
Provides the Act’s short titles: the “Strengthening Tools to Outlaw Poisonous Nitazenes Act” and the “STOP Nitazenes Act.” This is purely nominative but is the label under which affected stakeholders and agencies will reference the statutory changes in guidance and rulemaking.
Addition to Schedule I — class-based listing for nitazenes
Amends 21 U.S.C. 812(c) by adding a new subsection that treats as Schedule I any material containing any quantity of a “2-benzylbenzimidazole opioid,” unless specifically exempted or listed in another schedule. The practical mechanics: (1) the language is explicitly broad — it sweeps in any quantity and expressly covers salts and isomers; (2) the definition is tripartite (structural characteristics, pharmacological activity, and an enumerated sample list), which is designed to capture both known nitazenes and many analogues that chemists could create; and (3) the Attorney General can publish a clarifying list in the Federal Register, which will serve as the operational reference for enforcement and testing labs.
Conversion of temporary schedules to permanent status
Declares that any substance that was temporarily scheduled under the CSA’s emergency scheduling authority (21 U.S.C. 811(h)) and falls within the new subsection is automatically treated as permanently listed in Schedule I as of enactment. The provision removes the need for a separate, subsequent scheduling action for those specific temporarily scheduled nitazenes and locks their legal status into the CSA immediately.
Implementation deadline and interim rule authority
Directs the Attorney General to issue rules implementing the Act within one year of enactment and authorizes the use of an interim final rule. That gives the DEA a statutory deadline to publish regulatory details — for example, analytical definitions, registration requirements, or enforcement guidance — and to do so without initial notice-and-comment delay if it issues an interim final rule.
APA procedure for interim and final rules
States that an interim final rule may be made immediately effective without the usual APA good-cause demonstration, requires the interim rule to provide opportunities for comment and requests for hearings, and mandates that the Attorney General issue a final rule after those proceedings in accordance with section 553 of title 5. This creates an expedited administrative path while preserving the post-implementation comment/hearing process and a later, APA-compliant final regulation.
This bill is one of many.
Codify tracks hundreds of bills on Criminal Justice across all five countries.
Explore Criminal Justice in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Federal, state, and local law enforcement and prosecutors — gain a class-based Schedule I listing that reduces the need to prove novel analog status and simplifies charging decisions against nitazene-related trafficking and possession.
- Communities affected by nitazene overdoses and public-health agencies — stand to benefit from a statutory tool meant to reduce supply and distribution of extremely potent synthetic opioids.
- Medical examiners and forensic toxicology units — acquire statutory backing to prioritize testing and attribution for nitazenes when investigating overdoses, since the Schedule I listing clarifies legal classification.
Who Bears the Cost
- Academic and pharmaceutical researchers working on opioid pharmacology — will face higher regulatory hurdles, because Schedule I status requires stricter DEA registration, storage, and recordkeeping that slow or deter clinical and preclinical research.
- Forensic, clinical, and public-health labs — will need updated analytical methods, potentially new DEA registration or chain-of-custody procedures, and incur costs to validate tests for a broad class of analogues and their isomers/salts.
- Manufacturers, chemical suppliers, and importers of precursor chemicals or novel analogues — face compliance burdens, potential criminal exposure if shipments contain trace quantities, and supply-chain disruption while businesses adapt to the new classification.
- Harm-reduction programs and community-based testing services — may encounter legal and operational barriers when acquiring reagents or conducting on-site testing of suspected nitazenes under Schedule I constraints.
Key Issues
The Core Tension
The central dilemma is speed versus precision: the bill prioritizes rapid, broad legal control of a fast-moving class of lethal synthetic opioids to protect public safety, but that breadth and speed restrict legitimate research, create compliance and analytical uncertainty for labs and suppliers, and raise due-process questions about notice and definitional clarity.
The bill solves the problem of rapid chemical modification by making the scheduling criterion structural and pharmacological rather than tied to a single, named molecule. That prevents straightforward workarounds but raises practical implementation problems.
The structural language is technically detailed yet open-ended; it will require the Attorney General (and DEA) to translate chemical descriptions into analytically measurable definitions that labs can use to distinguish covered from non-covered substances. Without analytical thresholds or enumerated confirmatory tests in the statute, laboratories and courts will look to DEA rulemaking and published lists to establish operational standards.
Another tension is the use of “any quantity” and the inclusion of salts and isomers. Those phrases are purposeful to capture trace analogues and derivative forms, but they also risk criminalizing contamination and low-level presence that may be incidental or analytically ambiguous.
The automatic conversion of temporarily scheduled substances to permanent Schedule I status removes an interim period during which additional data could inform a narrower, substance-by-substance approach. Finally, the bill’s procedural shortcut — allowing an interim final rule to become effective without a good-cause showing — accelerates control but reduces pre-enforcement notice; affected parties will need to watch the Federal Register closely because compliance obligations can arrive before formal APA vetting is complete.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.